T&R Biofab announced on the 4th that it has obtained domestic sales approval from the Ministry of Food and Drug Safety for the ‘matrix formulation composite hemostatic agent’ (absorbable internal hemostatic product) developed in collaboration with REYON Pharmaceutical. This is a hemostatic medical device that quickly stops bleeding from wounds due to surgery and helps with wound tissue recovery. It is made by fusing ECM (extracellular matrix) material manufactured using patented technology with thrombin from REYON Pharmaceutical. Thrombin is a hemostatic active substance that promotes blood coagulation. The company explained that it has proven high safety and quality by passing the medical device Class 4 review, the highest grade in Korea.
Hanmi Pharmaceutical announced on the 4th that it presented a poster on the results of non-clinical studies for its next-generation targeted anticancer innovative drug ‘HM97662’ at the 18th International Conference on Malignant Lymphoma (ICML2025) held last month in Lugano, Switzerland. HM97662 is a dual inhibitor of EZH1 and EZH2. In this study conducted on a B-cell lymphoma model, HM97662 showed significant tumor growth inhibition efficacy even with monotherapy. It more strongly inhibited the trimethylation of histone protein H3 at position 27 (H3K27me3) depending on the dosage compared to the existing treatment, Tazemetostat, which selectively inhibits EZH2, in B-cell lymphoma (KARPAS-422) and multiple myeloma (MM1.S) cell lines.
Kangstem Biotech announced on the 4th that it has completed the registration of a patent for a formulation containing Cutibacterium acnes as an active ingredient for the prevention, treatment, and improvement of atopic dermatitis. The company explained that it confirmed through a skin organoid-based atopic dermatitis model that the balance of beneficial bacteria and harmful bacteria (skin resident bacteria) on the skin is effective for the prevention and treatment of atopy.
The Ministry of Food and Drug Safety’s National Institute of Food and Drug Safety Evaluation (NIFDS) announced on the 4th that out of the items that received pre-consultation for the swift commercialization of innovative products such as pharmaceuticals, biopharmaceuticals, and medical devices over the past four years, 65 have entered the clinical trial stage. Among the 447 products that received pre-consultation from August 2020 to December last year, the results of an investigation on the 203 products that responded found that 2 pharmaceuticals and 17 medical devices completed their approvals and certifications, while 48 pharmaceuticals and 17 medical devices entered the clinical trial stage.
Pharmbio Korea announced on the 4th that it delivered research funding to Professor Park Ye-hyun of Ewha Womans University, who was selected as a recipient of the ‘2nd Bonghwa Research Fund’ at the recently held 2025 Korean Society of Gastroenterology Multi-center Research Festival. Professor Park received funding for her project titled ‘Analysis of the Effects of Ant obesity Drugs on the Intestinal Microbiome and Metabolome in Patients with Inflammatory Bowel Disease: A Multi-center Prospective Cohort Study (IBD Research Group).’
Dongkook Pharmaceutical held the ‘DKMA Busan Symposium’ at the Signiel Hotel in Haeundae, Busan, on the 28th of last month, where it conducted lectures on the action principles, characteristics, and procedures of its main products, including hyaluronic acid fillers and botulinum toxin. The company also announced that it unveiled a new skin booster based on chitosan and TECA, which is set to launch in the latter half of this year.
Yongma Logis announced on the 4th that it has passed the follow-up audit for the Information Security Management System (ISMS) international standard certification ‘ISO 27001’ from the Korea Quality Foundation. ISO 27001 is the international certification related to information security management systems established by the International Organization for Standardization (ISO). The company first obtained this certification last year, and certified corporations must undergo follow-up audits annually.
The Association of Korean Medicine (AKOM) announced that it will hold a National Assembly Forum titled ‘The Future of Integrated Care in an Ultra-Aging Society: The Role of Integrated Support Law and Korean Medicine’ at the seventh meeting room of the National Assembly in Yeouido, Seoul, starting at 2 p.m. on the 8th. This event is co-hosted by the National Assembly ‘Health, Care, and Human Rights Forum’ and National Assembly members Seo Byung-hoon, Seo Young-seok, Park Soo-hyun, Lim Oh-kyung, Ahn Do-geol, Kim Sang-wook, and Mo Gyeong-jong.